Annual DHL Express ‘Rakhi Express' Campaign Offers Discounts on International Shipments, Starting at INR 3,099* All Inclusive
DHL Express, the global leader in international express logistics, has launched its annual festive offering 'Rakhi Express', bridging distances and helping customers celebrate the cherished bond of Raksha Bandhan with their family. The initiative offers attractive discounts, with a flat fee starting from INR 3,099* on international Rakhi and gift shipments. The offer is valid across DHL's robust network of 700+ retail outlets nationwide and on its official website, until 9 August 2025.
Business Wire India
The discount will be valid until 9 August 2025
The discounted rate starts from INR 3,099* on international rakhi and gift shipments and INR 250 on domestic shipments.
The offer is available for international shipments at over 700 DHL Express and Blue Dart retail outlets and via the DHL India website
DHL Express, the global leader in international express logistics, has launched its annual festive offering 'Rakhi Express', bridging distances and helping customers celebrate the cherished bond of Raksha Bandhan with their family. The initiative offers attractive discounts, with a flat fee starting from INR 3,099* on international Rakhi and gift shipments. The offer is valid across DHL's robust network of 700+ retail outlets nationwide and on its official website, until 9 August 2025. Customers choosing to avail the offer in-store simply need to use the PROMO code *RAKHIGIFTS* while booking their shipment at the store.
Raksha Bandhan celebrates the bond between siblings, specifically the love and protection that each sibling offers to the other. In today's interconnected world, families are often separated by borders due to academic pursuits, professional commitments, or lifestyle choices, making it challenging to celebrate festivals like Raksha Bandhan together. D HL Express aims to connect families celebrating the festival through 'Rakhi Express'.
Commenting on the initiative, Sandeep Juneja, Vice President – Commercial, DHL Express India, said, "At DHL, trade and connecting people are what we do best. During festivals like Raksha Bandhan, we want each of our customers to enjoy the nostalgia of 'home' even if they cannot be physically present with their loved ones. Every Raksha Bandhan, 'Rakhi Express' becomes a bridge of love for families separated by distance. This year, we have an exciting offer where international shipments can be shipped starting at INR 3,099*. With Rakhi Express, we aim to deliver excellence, but also joy, love, and the memories associated with the festival straight to our customers' doorsteps across the globe."
DHL Express' global network, covering over 220 countries and territories, ensures fast and reliable deliveries with end-to-end shipment visibility. Customers can track their packages, receive timely SMS and email updates, and also leverage services like on demand delivery to have more control over how their shipments are delivered to them, ensuring a smooth delivery experience.
To inquire about this offer, customers can contact DHL Express via the toll-free number 1800 30 345, visit the enquiry page or visit the DHL website to get a quote and book a shipment online.
*T&C Apply
Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same.
Ahmedabad Plane Crash
Business Wire India, established in 2002, India's premier media distribution company ensures guaranteed media coverage through its network of 30+ cities and top news agencies.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 hours ago
- Yahoo
DHL moves early to renew Cargojet contract until 2033
Canadian airline Cargojet has extended its long-term transport agreement with integrated carrier DHL Express until March 31, 2033, and reduced DHL's potential ownership stake in the company from 9.5% to 6.6% in exchange for renewing the deal two years before it expired, the companies announced Wednesday. The revised freight services contract is projected to deliver $2.3 billion in revenue for Cargojet. DHL has the right to extend the agreement two times for two-year terms, potentially stretching the deal until March 2037. Cargojet was scheduled to release second-quarter results Wednesday after the stock market closed, but had not done so as of 7 p.m. ET. In early July, Cargojet extended its contract with Amazon for four years. The contract now runs until March 31, 2029. Cargojet began flying in DHL's express package network in 2005. It now provides bundled lease packages that include aircraft, crews and mechanics to fly freight; crew and maintenance in cases where DHL provides its own freighter aircraft; and charter service for short-term capacity needs. Cargojet has a fleet of more than 40 Boeing 767 and 757 freighters. Some of DHL's volume moves in Cargojet's domestic Canadian overnight network in which capacity is shared by various customers. Cargojet's current contract with DHL was signed in March 2022 and was scheduled to run five years. The companies cemented their partnership with the issuance of warrants giving DHL 9.5% of Cargojet shares after a seven-year vesting period. Under the expanded partnership, DHL will continue to guarantee a minimum amount of paid flight hours per month and give Cargojet preference to fly additional routes as it adjusts its global network to meet shipping demand. Cargojet will also terminate the warrants to acquire more than 1.6 million voting shares and instead issue warrants giving DHL the right to acquire 1 million shares at a price of $67.90 per share over a period of eight years, with vesting tied to DHL delivering up to $3.2 billion in business volume during the period. Click here for more FreightWaves/American Shipper stories by Eric Kulisch. Write to Eric Kulisch at ekulisch@ RELATED STORIES: New US de minimis policy could trim DHL profit by 3% Rise in China e-commerce traffic lifts Cargojet to record revenue The post DHL moves early to renew Cargojet contract until 2033 appeared first on FreightWaves. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14 hours ago
- Yahoo
Neogen Chemicals Ltd (BOM:542665) Q1 2026 Earnings Call Highlights: Resilience Amid Challenges ...
Release Date: August 04, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Neogen Chemicals Ltd (BOM:542665) demonstrated resilience by maintaining momentum despite operational challenges due to a fire incident. The company reported sustained volume growth in its base business, contributing to its financial performance. Initial commercial sales from Neogen Ionics for both electrolyte and lithium salts began contributing meaningfully to the company's revenue. The company has secured initial insurance claims of INR 50.55 crore in June 2025 and an additional INR 30 crore in July 2025, aiding recovery from the fire incident. Neogen Chemicals Ltd (BOM:542665) is making significant progress in its strategic growth drivers, particularly in the battery chemicals segment, with ongoing expansion initiatives. Negative Points The company faced operational hurdles due to a fire incident, impacting the availability of its H plant for the quarter. There is a prevailing soft pricing environment, which could affect profitability. The retirement of Chairman and Managing Director Mr. Haridas Kanani may lead to transitional challenges. The company adjusted its near-term revenue guidance to reflect current operational realities, indicating potential short-term financial pressure. There are delays in product approvals and customer audits, particularly affecting the ramp-up of export revenues. Q & A Highlights Warning! GuruFocus has detected 4 Warning Signs with BOM:542665. Q: What is the status of product approvals for the salt business, and how is the export revenue ramp-up progressing? A: We are ready from our side and waiting for the customer to schedule an audit. There have been delays from the customer side due to current events in the US. We are also ramping up our H capacity, which will increase to 2,500 metric tons by March. Meanwhile, we are generating small revenue by selling to non-regulated markets like China. (Respondent: Unidentified_3) Q: From a key end-user market perspective, will the US or Europe be bigger, and is there any change in demand due to tariff uncertainties? A: The US is the larger market due to established battery manufacturing activities. Despite changes in IRA, the 45X credits for cell makers remain, which require localization and a China-free supply chain. Interest from international markets is growing stronger, and more companies are approaching Neogen for partnerships. (Respondent: Unidentified_3) Q: What is the typical time lag required to increase salt capacity given the demand and interest? A: We are targeting 2,500 metric tons and can increase by 1,000 metric tons more, focusing on additives. We have room to add 1 KTA at the H facility and 2 additional KTA at Pahagen. We can add 3 KTA relatively quickly within 6 to 9 months, but beyond 8.5 KTA, it will take 12 to 15 months to set up a new manufacturing block. (Respondent: Unidentified_3) Q: Can you share the volume growth numbers for the first quarter across businesses? A: On the organic side, volume growth is around 10 to 15%. On the lithium side, there was a big growth last quarter, but Q1 was softer than usual. However, demand continues, and by the end of the year, lithium volumes should match or slightly exceed previous levels. (Respondent: Unidentified_3) Q: What is the purpose of the NCD issue, and is it for working capital or something else? A: The NCD issue is to ensure smooth CapEx execution and not be fully dependent on insurance claims. It provides additional liquidity to manage timing mismatches in insurance receipts and ongoing CapEx projects. The NCD issuance is expected to happen within the current month. (Respondent: Unidentified_3) For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
15 hours ago
- Business Upturn
BeOne Medicines Announces Second Quarter 2025 Financial Results and Business Updates
By Business Wire India Published on August 6, 2025, 18:56 IST Business Wire India Second quarter total revenues increased 42% to $1.3 billion versus second quarter 2024 Global BRUKINSA revenues increased 49% to $950 million versus second quarter 2024 Reported diluted GAAP Earnings per American Depositary Share (ADS) of $0.84, non-GAAP diluted Earnings per ADS of $2.25 Anticipate 20+ milestones in next 18 months across hematology and solid tumor pipeline BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the second quarter of 2025. 'Our strong second quarter performance reinforces our trajectory as a global oncology powerhouse and underscores our proven ability to deliver sustainable, long-term growth,' said John V. Oyler, Co-Founder, Chairman and CEO of BeOne. 'We are executing with purpose and advancing our mission to deliver transformative medicines to more patients worldwide. BRUKINSA, the backbone of our hematology franchise, continues to set the standard as the best-in-class BTK inhibitor with the most approved indications and market leader in the US, a position earned from superior efficacy, favorable safety, and positive patient outcomes across its five indications. Building on this momentum, our two additional Phase 3 hematology assets, BCL2 inhibitor sonrotoclax and BTK CDAC BGB-16673, have the potential to further expand our franchise leadership with pivotal data readouts and new trial initiations anticipated in the near-term. At our recent Investor R&D Day, we outlined a bold path forward with more than 20 expected R&D milestones in the next 18 months. This includes potentially promising advances across our expansive solid tumor pipeline, where we are building future global franchises targeting a range of highly prevalent cancers.' (Amounts in thousands of U.S. dollars and unaudited) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 % Change 2025 2024 % Change Net product revenues $ 1,302,076 $ 921,146 41 % $ 2,410,606 $ 1,668,064 45 % Net revenue from collaborations $ 13,224 $ 8,020 65 % $ 21,973 $ 12,754 72 % Total revenue $ 1,315,300 $ 929,166 42 % $ 2,432,579 $ 1,680,818 45 % GAAP income (loss) from operations $ 87,885 $ (107,161 ) 182 % $ 98,987 $ (368,509 ) 127 % Adjusted income (loss) from operations* $ 274,945 $ 48,464 467 % $ 414,302 $ (98,877 ) 519 % GAAP net income (loss) $ 94,320 $ (120,405 ) 178 % $ 95,590 $ (371,555 ) 126 % Adjusted net income (loss)* $ 252,822 $ 23,294 985 % $ 388,959 $ (122,602 ) 417 % GAAP basic EPS per ADS $ 0.87 $ (1.15 ) 176 % $ 0.89 $ (3.56 ) 125 % Adjusted basic EPS per ADS* $ 2.33 $ 0.22 959 % $ 3.61 $ (1.17 ) 409 % GAAP diluted EPS per ADS $ 0.84 $ (1.15 ) 173 % $ 0.85 $ (3.56 ) 124 % Adjusted diluted EPS per ADS* $ 2.25 $ 0.22 923 % $ 3.48 $ (1.17 ) 397 % Free Cash Flow* $ 219,772 $ (205,538 ) 207 % $ 207,447 $ (670,688 ) 131 % * For an explanation of our use of non-GAAP financial measures refer to the 'Note Regarding Use of Non-GAAP Financial Measures' section later in this press release and for a reconciliation of each non-GAAP financial measure to the most comparable GAAP measures, see the table at the end of this press release. Second Quarter 2025 Financial Results Revenue for the second quarter of 2025 was $1.3 billion, compared to $929 million in the prior-year period driven primarily by growth in BRUKINSA (zanubrutinib) product sales in the U.S. and Europe. Product Revenue totaled $1.3 billion for the second quarter of 2025 compared to $921 million in the prior-year period. The increase in product revenue was primarily attributable to increased sales of BRUKINSA. The U.S. continued to be the Company's largest market, with product revenue of $685 million compared to $479 million in the prior-year period. In-licensed products from Amgen and TEVIMBRA (tislelizumab) also contributed to product revenue growth. U.S. sales of BRUKINSA totaled $684 million in the second quarter of 2025, representing growth of 43% over the prior-year period driven primarily by robust demand growth across all indications and modest benefit due to net pricing. BRUKINSA continues to maintain its leading new patient share across the BTKi class due to its differentiated, best-in-class clinical profile. BRUKINSA sales in Europe totaled $150 million in the second quarter of 2025, representing growth of 85% compared to the prior-year period, driven by increased market share across all major European markets, including Germany, Italy, Spain, France and the UK. Sales of TEVIMBRA totaled $194 million in the second quarter of 2025, representing growth of 22% compared to the prior-year period. Gross Margin as a percentage of global product sales for the second quarter of 2025 was 87.4% compared to 85.0% in the prior-year period on a GAAP basis. The gross margin percentage increased due to a proportionally higher sales mix of global BRUKINSA compared to other products in our portfolio. Gross margin also benefited from cost of sales productivity improvements for both BRUKINSA and TEVIMBRA. On an adjusted basis, which does not include depreciation and amortization, gross margin as a percentage of product sales increased to 88.1% for the second quarter of 2025, compared to 85.4% in the prior-year period. Operating Expenses The following table summarizes operating expenses for the second quarter of 2025: GAAP Non-GAAP (unaudited, in thousands, except percentages) Q2 2025 Q2 2024 % Change Q2 2025 Q2 2024 % Change Research and development $ 524,896 $ 454,466 15 % $ 444,057 $ 382,509 16 % Selling, general and administrative $ 537,913 $ 443,729 21 % $ 441,655 $ 363,922 21 % Total operating expenses $ 1,062,809 $ 898,195 18 % $ 885,712 $ 746,431 19 % The following table summarizes operating expenses for the first half of 2025: GAAP Non-GAAP (unaudited, in thousands, except percentages) Q2 YTD 2025 Q2 YTD 2024 % Change Q2 YTD 2025 Q2 YTD 2024 % Change Research and development $ 1,006,783 $ 915,104 10 % $ 865,252 $ 787,949 10 % Selling, general and administrative $ 997,201 $ 871,156 14 % $ 837,166 $ 736,068 14 % Total operating expenses $ 2,003,984 $ 1,786,260 12 % $ 1,702,418 $ 1,524,017 12 % Research and Development (R&D) Expenses increased for the second quarter of 2025 compared to the prior-year period on both a GAAP and adjusted basis primarily due to advancing preclinical programs into the clinic and early clinical programs into late stage, and offset by lower development upfront and milestone fees. Upfront fees and milestone payments related to in-process R&D for in-licensed assets totaled $0.5 million and $12 million in the second quarter of 2025 and 2024, respectively. Selling, General and Administrative (SG&A) Expenses increased for the second quarter of 2025 compared to the prior-year period on both a GAAP and adjusted basis due to continued investment in global commercial expansion, primarily in the U.S. and Europe. SG&A expenses as a percentage of product sales were 41% for the second quarter of 2025, compared to 48% in the prior-year period. Net Income/(Loss) and GAAP/Non-GAAP Earnings Per Share GAAP net income for the second quarter of 2025 was $94 million, an increase of $215 million over the prior-year period loss, primarily attributable to revenue growth and improved operating leverage. For the second quarter of 2025, basic and diluted earnings per share was $0.07 and $0.06 per share and $0.87 and $0.84 per American Depositary Share (ADS), respectively, compared to basic loss of $0.09 per share and $1.15 per ADS in the prior-year period. Free Cash Flow for the second quarter of 2025 was $220 million, an increase of $425 million over the prior-year period. For further details on BeOne's Second Quarter 2025 Financial Statements, please see BeOne's Quarterly Report on Form 10-Q for the second quarter of 2025 filed with the U.S. Securities and Exchange Commission. Full Year 2025 Guidance BeOne has updated its full year 2025 revenue guidance and maintained its expense guidance. Guidance is summarized below: Prior FY 2025 Guidance1 Current FY 2025 Guidance1 Total Revenue $4.9 – $5.3B $5.0 – $5.3B GAAP Operating Expenses (R&D and SG&A) $4.1 – $4.4B $4.1 – $4.4B GAAP Gross Margin % Mid-80% range Mid to high-80% range GAAP Operating Income Positive FY 2025 Positive FY 2025 Cash Flow Positive FY 2025 cash flow from operations Positive FY 2025 free cash flow 1 Does not assume any potential new, material business development activity or unusual/non-recurring items. Assumes June 30, 2025 foreign exchange rates. BeOne's total revenue guidance for full year 2025 of $5.0 billion to $5.3 billion includes expectations for strong revenue growth driven by BRUKINSA's U.S. leadership position and continued global expansion in both Europe and other important rest of world markets. Gross margin percentage is expected to be in the mid- to high-80% range due to mix and production efficiencies as compared to 2024. BeOne's guidance for combined operating expenses on a GAAP basis includes expectations of investment to support growth in both commercial and research at a pace that continues to deliver meaningful operating leverage. Non-GAAP operating expenses, which exclude costs related to share-based compensation, depreciation and amortization expense, are expected to track with GAAP operating expenses, with reconciling items unchanged from existing practice. Operating expense guidance does not assume any potential new, material business development activity or unusual/non-recurring items. Second Quarter Business Highlights Core Marketed Products BRUKINSA(zanubrutinib) BRUKINSA is now approved in 75 markets globally with five new or expanded reimbursements in the quarter. Received U.S. Food and Drug Administration (FDA) approval and a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval of a new film-coated tablet formulation for all approved indications. TEVIMBRA(tislelizumab) TEVIMBRA is now approved in 47 markets globally with 20 new reimbursements in the quarter, including in Japan, Europe and Australia. Received European Commission (EC) approval in combination with gemcitabine and cisplatin for the first-line treatment of adult patients with metastatic or recurrent nasopharyngeal carcinoma. Received EC approval for the treatment of first-line extensive-stage small cell lung cancer. Received a positive CHMP opinion recommending approval of TEVIMBRA in combination with platinum-containing chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment, for the treatment of adult patients with resectable non-small cell lung cancer (NSCLC) at high risk of recurrence. Received FDA approval of alternative dosing regimens of 150 Q2W and 300 Q4W for the treatment of first-line gastric cancer and second-line esophageal squamous cell carcinoma. Select Clinical-Stage Programs Hematology Sonrotoclax (BCL2 inhibitor): Achieved acceptance of submissions in China with priority reviews for the treatment of relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and R/R mantle cell lymphoma (MCL). Achieved first subject enrolled in global Phase 3 trial in combination with CD20 antibody for the treatment of R/R CLL. Received EMA PRIority MEdicines (PRIME) designation for the treatment of patients with Waldenstrom's macroglobulinemia (WM) previously treated with a BTK inhibitor. Achieved first subject enrolled for global Phase 3 BGB-16673-302 trial for the treatment of R/R CLL. Achieved first subject enrolled for China Phase 3 BGB-16673-303 trial for the treatment of R/R/ CLL. Initiated enrollment of potentially registration enabling Phase 2 trial for the treatment of R/R WM. Lung Cancer Tarlatamab (AMG 757): Achieved acceptance of BLA and priority review in China for the treatment of 3L+ small cell lung cancer (SCLC). Achieved acceptance of BLA in China for the treatment of 2L SCLC. GI Cancers Zanidatamab (HER2-targeting bispecific antibody): Received regulatory approval and achieved commercial launch in China for the treatment of second-line HER2-high-expression biliary tract cancer. Inflammation & Immunology BGB-45035 (IRAK4 CDAC): Achieved first subject enrolled in Phase 1b trial for the treatment of atopic dermatitis and prurigo nodularis. BGB-16673 (BTK CDAC): Achieved first subject enrolled in Phase 1 trial for the treatment of chronic spontaneous urticaria. Anticipated R&D Milestones Programs Milestones Timing BRUKINSA EC approval of tablet formulation. Interim analysis of Phase 3 MANGROVE trial for the treatment of treatment-naïve MCL. 2H 2025 2H 2025 TEVIMBRA EU approval for the treatment of neoadjuvant and adjuvant early stage NSCLC. Initiate Phase 3 trial for subcutaneous formulation. 2H 2025 2H 2025 Hematology Sonrotoclax: Data readout of Phase 2 trial and potential global accelerated approval submissions for the treatment of R/R MCL. BGB-16673: Initiate Phase 3 head-to-head trial compared to noncovalent BTK inhibitor pirtobrutinib for the treatment of R/R CLL. 2H 2025 2H 2025 Breast Cancer BGB-43395 (CDK4 inhibitor): Initiate Phase 3 trial for the treatment of second-line hormone receptor-positive, HER2-negative metastatic breast cancer. Initiate Phase 3 trial for the treatment of first-line hormone receptor-positive, HER2-negative metastatic breast cancer. 2026 2026 Lung Cancer BGB-58067 (PRMT5 inhibitor) and BG-89894 (MAT2A inhibitor): Anticipate first subject enrolled in combination trial. 2H 2025 GI Cancers Zanidatamab (HER2-targeting bispecific antibody): Readout of primary progression-free survival data from Phase 3 trial in collaboration with Zymeworks/Jazz for the treatment of first-line HER2-positive gastroesophageal adenocarcinoma. 2H 2025 Inflammation and Immunology BGB-45035 (IRAK4 CDAC): Anticipate first subject enrolled in Phase 2 trials. Proof-of-concept data for tissue IRAK4 degradation. 2H 2025 2H 2025 Other Highlights Completed renaming to BeOne Medicines Ltd., and redomiciliation to Switzerland. Conference Call and Webcast The Company's earnings conference call for the second quarter 2025 will be broadcast via webcast at 8:00 a.m. ET on Wednesday, August 6, 2025, and will be accessible through the Investors section of BeOne's website at Supplemental information in the form of a slide presentation and a replay of the webcast will also be available. About BeOne BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of more than 11,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them. To learn more about BeOne, please visit and follow us on LinkedIn, X, Facebook and Instagram. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding: upcoming R&D milestones to be achieved by BeOne; the timing of clinical developments and data readouts; BeOne's expectations regarding continued global expansion and investment to support growth; BeOne's ability to bring transformative medicines to more patients worldwide; BeOne's future revenue, operating income, cash flow, free cash flow, operating expenses, and gross margin percentage; and BeOne's plans, commitments, aspirations and goals under the caption 'About BeOne'. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeOne's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne's reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne's limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeOne's ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled 'Risk Factors' in BeOne's most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law. BeOne's financial guidance is based on estimates and assumptions that are subject to significant uncertainties. Condensed Consolidated Statements of Operations (U.S. GAAP) (Amounts in thousands of U.S. dollars, except for shares, American Depositary Shares (ADSs), per share and per ADS data) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 (Unaudited) (Unaudited) Revenues Product revenue, net $ 1,302,076 $ 921,146 $ 2,410,606 $ 1,668,064 Collaboration revenue 13,224 8,020 21,973 12,754 Total revenues 1,315,300 929,166 2,432,579 1,680,818 Cost of sales – products 164,606 138,132 329,608 263,067 Gross profit 1,150,694 791,034 2,102,971 1,417,751 Operating expenses: Research and development 524,896 454,466 1,006,783 915,104 Selling, general and administrative 537,913 443,729 997,201 871,156 Total operating expenses 1,062,809 898,195 2,003,984 1,786,260 Income (loss) from operations 87,885 (107,161 ) 98,987 (368,509 ) Interest income, net 3,497 13,225 9,345 29,385 Other income (expense), net 8,167 (11,984 ) 12,117 (10,222 ) Income (loss) before income taxes 99,549 (105,920 ) 120,449 (349,346 ) Income tax expense 5,229 14,485 24,859 22,209 Net income (loss) $ 94,320 $ (120,405 ) 95,590 (371,555 ) Earnings (loss) per share Basic $ 0.07 $ (0.09 ) 0.07 (0.27 ) Diluted $ 0.06 $ (0.09 ) 0.07 (0.27 ) Weighted-average shares outstanding—basic 1,408,166,754 1,361,082,567 1,399,159,898 1,358,315,145 Weighted-average shares outstanding—diluted 1,463,277,401 1,361,082,567 1,454,296,475 1,358,315,145 Earnings (loss) per American Depositary Share (ADS) Basic $ 0.87 $ (1.15 ) 0.89 (3.56 ) Diluted $ 0.84 $ (1.15 ) 0.85 (3.56 ) Weighted-average ADSs outstanding—basic 108,320,520 104,698,659 107,627,684 104,485,780 Weighted-average ADSs outstanding—diluted 112,559,800 104,698,659 111,868,960 104,485,780 Select Condensed Consolidated Balance Sheet Data (U.S. GAAP) (Amounts in thousands of U.S. Dollars) As of June 30, December 31, 2025 2024 (unaudited) (audited) Assets: Cash, cash equivalents and restricted cash $ 2,786,086 $ 2,638,747 Accounts receivable, net 770,776 676,278 Inventories 502,867 494,986 Property, plant and equipment, net 1,615,792 1,578,423 Total assets 6,298,394 5,920,910 Liabilities and equity: Accounts payable 360,783 404,997 Accrued expenses and other payables 908,882 803,713 R&D cost share liability 119,871 165,440 Debt 954,485 1,018,013 Total liabilities 2,527,919 2,588,688 Total equity $ 3,770, 475 $ 3,332,222 Select Unaudited Condensed Consolidated Statements of Cash Flows (U.S. GAAP) (Amounts in thousands of U.S. Dollars) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 (unaudited) (unaudited) Cash, cash equivalents and restricted cash at beginning of period $ 2,530,591 $ 2,807,436 $ 2,638,747 $ 3,185,984 Net cash provided by (used in) operating activities 263,598 (95,588 ) 307,680 (404,160 ) Net cash used in investing activities (66,605 ) (111,032 ) (188,546 ) (320,863 ) Net cash provided by financing activities 35,025 23,017 1,248 185,310 Net effect of foreign exchange rate changes 23,477 (5,902 ) 26,957 (28,340 ) Net increase (decrease) in cash, cash equivalents, and restricted cash 255,495 (189,505 ) 147,339 (568,053 ) Cash, cash equivalents and restricted cash at end of period $ 2,786,086 $ 2,617,931 $ 2,786,086 $ 2,617,931 Note Regarding Use of Non-GAAP Financial Measures BeOne provides certain non-GAAP financial measures, including Adjusted Operating Expenses, Adjusted Operating Loss, Adjusted Net Income, Adjusted Earnings Per Share and certain other non-GAAP income statement line items, each of which include adjustments to GAAP figures. These non-GAAP financial measures are intended to provide additional information on BeOne's operating performance. Adjustments to BeOne's GAAP figures exclude, as applicable, non-cash items such as share-based compensation, depreciation and amortization. Certain other special items or substantive events may also be included in the non-GAAP adjustments periodically when their magnitude is significant within the periods incurred. Non-GAAP adjustments are tax effected to the extent there is U.S. GAAP current tax expense. The Company currently records a valuation allowance on its net deferred tax assets, so there is no net impact recorded for deferred tax effects. BeOne maintains an established non-GAAP policy that guides the determination of what costs will be excluded in non-GAAP financial measures and the related protocols, controls and approval with respect to the use of such measures. BeOne believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of BeOne's operating performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of BeOne's historical and expected financial results and trends and to facilitate comparisons between periods and with respect to projected information. In addition, these non-GAAP financial measures are among the indicators BeOne's management uses for planning and forecasting purposes and measuring BeOne's performance. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by BeOne may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies. RECONCILIATION OF SELECTED GAAP MEASURES TO NON-GAAP MEASURES (Amounts in thousands of U.S. Dollars) (unaudited) Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024 Reconciliation of GAAP to adjusted cost of sales – products: GAAP cost of sales – products $ 164,606 $ 138,132 $ 329,608 $ 263,067 Less: Depreciation 3,321 2,684 5,934 5,029 Less: Amortization of intangibles 5,749 1,177 6,922 2,360 Less: Other 893 — 893 — Adjusted cost of sales – products $ 154,643 $ 134,271 $ 315,859 $ 255,678 Reconciliation of GAAP to adjusted research and development: GAAP research and development $ 524,896 $ 454,466 $ 1,006,783 $ 915,104 Less: Share-based compensation cost 64,392 55,406 106,159 93,451 Less: Depreciation 16,447 16,551 35,372 33,704 Adjusted research and development $ 444,057 $ 382,509 $ 865,252 $ 787,949 Reconciliation of GAAP to adjusted selling, general and administrative: GAAP selling, general and administrative $ 537,913 $ 443,729 $ 997,201 $ 871,156 Less: Share-based compensation cost 86,161 75,288 139,845 125,957 Less: Depreciation 10,086 4,519 20,162 9,131 Less: Amortization of intangibles 11 — 28 — Adjusted selling, general and administrative $ 441,655 $ 363,922 $ 837,166 $ 736,068 Reconciliation of GAAP to adjusted operating expenses GAAP operating expenses $ 1,062,809 $ 898,195 $ 2,003,984 $ 1,786,260 Less: Share-based compensation cost 150,553 130,694 246,004 219,408 Less: Depreciation 26,533 21,070 55,534 42,835 Less: Amortization of intangibles 11 — 28 — Adjusted operating expenses $ 885,712 $ 746,431 $ 1,702,418 $ 1,524,017 Reconciliation of GAAP to adjusted income (loss) from operations: GAAP income (loss) from operations $ 87,885 $ (107,161 ) $ 98,987 $ (368,509 ) Plus: Share-based compensation cost 150,553 130,694 246,004 219,408 Plus: Depreciation 29,854 23,754 61,468 47,864 Plus: Amortization of intangibles 5,760 1,177 6,950 2,360 Plus: Other 893 — 893 — Adjusted income (loss) from operations $ 274,945 $ 48,464 $ 414,302 $ (98,877 ) Reconciliation of GAAP to adjusted net income (loss): GAAP net income (loss) $ 94,320 $ (120,405 ) $ 95,590 $ (371,555 ) Plus: Share-based compensation expenses 150,553 130,694 246,004 219,408 Plus: Depreciation 29,854 23,754 61,468 47,864 Plus: Amortization of intangibles 5,760 1,177 6,950 2,360 Plus: Other 893 — 893 — Plus: Impairment of equity investments 3,118 — 15,494 — Plus: Discrete tax items (14,210 ) 1,513 (8,737 ) 2,403 Plus: Income tax effect of non-GAAP adjustments1 (17,466 ) (13,439 ) (28,703 ) (23,082 ) Adjusted net income (loss) $ 252,822 $ 23,294 $ 388,959 $ (122,602 ) Reconciliation of GAAP to adjusted EPS – basic GAAP earnings (loss) per share – basic $ 0.07 $ (0.09 ) $ 0.07 $ (0.27 ) Plus: Share-based compensation expenses 0.11 0.10 0.18 0.16 Plus: Depreciation 0.02 0.02 0.04 0.04 Plus: Amortization of intangibles 0.00 0.00 0.00 0.00 Plus: Other 0.00 0.00 0.00 0.00 Plus: Impairment of equity investments 0.00 0.00 0.01 0.00 Plus: Discrete tax items (0.01 ) (0.00 ) (0.01 ) 0.00 Plus: Income tax effect of non-GAAP adjustments1 (0.01 ) (0.01 ) (0.02 ) (0.02 ) Adjusted earnings (loss) per share – basic $ 0.18 $ 0.02 $ 0.28 $ (0.09 ) Reconciliation of GAAP to adjusted EPS – diluted GAAP earnings (loss) per share – diluted $ 0.06 $ (0.09 ) $ 0.07 $ (0.27 ) Plus: Share-based compensation expenses 0.10 0.09 0.17 0.16 Plus: Depreciation 0.02 0.02 0.04 0.04 Plus: Amortization of intangibles 0.00 0.00 0.00 0.00 Plus: Other 0.00 0.00 0.00 0.00 Plus: Impairment of equity investments 0.00 0.00 0.01 0.00 Plus: Discrete tax items (0.01 ) 0.00 (0.01 ) 0.00 Plus: Income tax effect of non-GAAP adjustments1 (0.01 ) (0.01 ) (0.02 ) (0.02 ) Adjusted earnings (loss) per share – diluted $ 0.17 $ 0.02 $ 0.27 $ (0.09 ) Reconciliation of GAAP to adjusted earnings (loss) per ADS – basic GAAP earnings (loss) per ADS – basic $ 0.87 $ (1.15 ) $ 0.89 $ (3.56 ) Plus: Share-based compensation expenses 1.39 1.25 2.29 2.10 Plus: Depreciation 0.28 0.23 0.57 0.46 Plus: Amortization of intangibles 0.05 0.01 0.06 0.02 Plus: Other 0.01 0.00 0.01 0.00 Plus: Impairment of equity investments 0.03 0.00 0.14 0.00 Plus: Discrete tax items (0.13 ) 0.01 (0.08 ) 0.02 Plus: Income tax effect of non-GAAP adjustments1 (0.16 ) (0.13 ) (0.27 ) (0.22 ) Adjusted earnings (loss) per ADS – basic $ 2.33 $ 0.22 $ 3.61 $ (1.17 ) Reconciliation of GAAP to adjusted earnings (loss) per ADS – diluted GAAP earnings (loss) per ADS – diluted2 $ 0.84 $ (1.13 ) $ 0.85 $ (3.56 ) Plus: Share-based compensation expenses 1.34 1.23 2.20 2.10 Plus: Depreciation 0.27 0.22 0.55 0.46 Plus: Amortization of intangibles 0.05 0.01 0.06 0.02 Plus: Other 0.01 0.00 0.01 0.00 Plus: Impairment of equity investments 0.03 0.00 0.14 0.00 Plus: Discrete tax items (0.13 ) 0.01 (0.08 ) 0.02 Plus: Income tax effect of non-GAAP adjustments1 (0.16 ) (0.13 ) (0.26 ) (0.22 ) Adjusted earnings (loss) per ADS – diluted $ 2.25 $ 0.22 $ 3.48 $ (1.17 ) Tax effect of Non-GAAP adjustments is based on the statutory tax rate in the relevant tax jurisdiction. Please note that the Company currently records a valuation allowance on its net deferred tax assets, so there is no net impact recorded for deferred tax effects. For the second quarter of 2024, GAAP diluted loss per ADS includes $0.02 loss per ADS attributable to the dilutive ADS outstanding for purposes of this reconciliation. As the Company was in a GAAP net loss position no diluted weighted average shares outstanding were calculated for US GAAP purposes. Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Free Cash Flow (Non-GAAP): Net cash provided by (used in) operating activities (GAAP) $ 263,598 $ (95,588 ) $ 307,680 $ (404,160 ) Less: Purchases of property, plant and equipment (43,826 ) (109,950 ) (100,233 ) (266,528 ) Free Cash Flow (Non-GAAP) $ 219,772 $ (205,538 ) $ 207,447 (670,688 ) View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same. Ahmedabad Plane Crash Business Wire India, established in 2002, India's premier media distribution company ensures guaranteed media coverage through its network of 30+ cities and top news agencies.
